A Connection Doctors Are Just Beginning to Map
Dermatologists have long observed that patients with inflammatory skin conditions frequently report gastrointestinal symptoms, and gastroenterologists notice that IBD patients disproportionately develop skin manifestations. The gut-skin axis formalises this clinical observation into a biological framework: gut microbial composition and metabolites influence systemic immune tone, which in turn modulates skin inflammation and barrier function.
Shared Immune Pathways
The gut and skin share critical immune infrastructure. Both organs maintain barrier function through epithelial tight junctions, antimicrobial peptide production, and a resident immune system. Both harbour their own microbiomes. And both communicate with systemic immunity through dendritic cells that migrate to draining lymph nodes and influence T cell polarisation. When gut dysbiosis shifts the balance toward pro-inflammatory Th17 responses (at the expense of regulatory T cells), this immune imbalance can manifest in distant organs — including the skin.
Condition-Specific Evidence
Acne vulgaris: Patients with acne show reduced gut microbial diversity and lower abundance of Lactobacillus and Bifidobacterium species compared to controls. Antibiotic treatment of acne (oral tetracyclines) may paradoxically worsen gut dysbiosis while improving skin, raising questions about the long-term gut-skin consequences of standard dermatological therapy.
Atopic dermatitis (eczema): The strongest gut-skin evidence exists for eczema, particularly in early life. Reduced gut microbial diversity in infants precedes and predicts eczema development. Bifidobacterium and Lactobacillus supplementation in pregnant women and infants has shown modest but consistent reduction in eczema incidence in meta-analyses — one of the few validated probiotic health claims.
Psoriasis: Psoriasis patients show gut dysbiosis patterns overlapping with IBD — decreased Faecalibacterium prausnitzii and increased Enterobacteriaceae. The shared IL-23/IL-17 inflammatory pathway connects intestinal and cutaneous inflammation, and biologic therapies targeting these cytokines improve both conditions simultaneously.
Rosacea: Rosacea is epidemiologically associated with SIBO, H. pylori infection, and IBS. Small studies suggest that treating SIBO or H. pylori can improve rosacea symptoms, though the evidence base remains limited.
Metabolite Mediators
Gut-derived metabolites that influence skin health include SCFAs (which modulate keratinocyte differentiation and skin immune responses through FFAR2 signalling), tryptophan metabolites (which activate aryl hydrocarbon receptors in skin immune cells), and secondary bile acids (which influence systemic inflammation). Conversely, increased intestinal permeability allowing LPS translocation raises systemic inflammatory tone, which can trigger or exacerbate skin flares.
Clinical Implications
The gut-skin axis is not yet a basis for established clinical guidelines, but it is reshaping dermatological thinking. Integrative approaches — combining topical skin treatment with dietary counselling, targeted probiotics (where evidence exists, particularly for eczema prevention), and addressing gut comorbidities — represent a more holistic treatment paradigm.